BIO Japan 2025

Myllia’s BD Manager, Henrik Schmidt, will be attending BIO Japan 2025 in Yokohama, Tokyo from October 8-10, 2025. We look forward to engaging with partners and new collaborators in the Japanese biotech and pharma market to discuss CRISPR-based target discovery in immunology and oncology research. At Myllia, we specialize in primary human cell CRISPR screens, particularly focusing on human immune cell populations such as CD3+ T cells, macrophages and dendritic cells.

Please get in touch with Myllia if you’d like to learn more about Myllia’s CROP-Seq screens and our proprietary VISTA platform for unbiased functional genomics screens!

Event website:
BIO Japan 2025

Attendee(s):
Henrik Schmidt (LinkedIn)